Science & Technology



Philadelphia pitches its bonafides to biotech CEOs at confab, and some even seemed impressed

Ellie Rushing, Philadelphia Inquirer on

Published in Science & Technology News

PHILADELPHIA -- Stanley Satz heard it all.

Speaker after speaker at the Comcast Technology Center extolled Philadelphia's world-class hospitals, its 63 universities, and the fact that billions of dollars in research funding have been bet on the city as the "epicenter of cell and gene therapy."

Their comments -- all a bid to attract new biotech businesses to Philadelphia -- were directed at folks like Satz, chief science officer and chairman of Advanced Innovative Partners, a Boca Raton, Fla.-based pharmaceutical firm that is developing products in cancer, neurology, and rare children's diseases.

"It was a great event," said Satz, who noted that his company already works on clinical trials at the University of Pennsylvania, just one of his firm's many ties to the area. When asked if he's planning to come to the city, he said, "What do you think?" with a grin. "We really might. We are thinking of opening a facility here."

The breakout event Monday was part of BIO 2019, the international biotechnology conference that has attracted more than 16,000 to the Convention Center and featured some of the city's best and brightest minds in the cell and gene-therapy industry. Their aim was to persuade a couple of hundred people in the audience to live up to the hash tag #ChoosePhilly when opening their next office.

"This is a sales pitch. We want you here in Philadelphia," said Daniel Hilferty, CEO of Independence Blue Cross, the region's largest health insurer. "We are on a mission to make sure you pick Philadelphia."


Emceed by NBC10 Philadelphia anchor Vai Sikahema, the event focused on five key players in the cell and gene-therapy industry: Carl June of Penn; Herve Hoppenot, CEO of Incyte in Wilmington; Bradley Campbell, chief operating officer of Amicus Therapeutics; Maria Fardis, CEO of Silicon-Valley-based Iovance Biotherapeutics; and Jeff Marrazzo, cofounder and CEO of Spark Therapeutics.

With 85 hospitals and clinics, and nearly 20% of the city's workforce employed in the health-care sector, the industry is close to making Philadelphia the "epicenter of cell and gene therapy."

"I think what we've done is we've gone through a tipping point," said June, who recalled how he was recruited to work at Penn in 1999 when the university was investing in new forms of gene therapy. The industry back then was limited by lack of money and investments, he said. Now, about $30 billion have been invested.

"A lot of ideas used to die because we didn't have the money to test. Now, that's over," he said. "I think we are past that tipping point and there's going to be this huge change in health care."


swipe to next page


blog comments powered by Disqus